Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special Reports
Special Reports
The top 10 drugs losing US exclusivity in 2025
Johnson & Johnson, Amgen, Regeneron, Novartis and other Big Pharma players are facing down sizable U.S. losses of exclusivity in 2025.
Eric Sagonowsky
,
Angus Liu
,
Fraiser Kansteiner
,
Andrea Park
,
Kevin Dunleavy
,
Zoey Becker
Mar 17, 2025 3:00am
Top 10 most anticipated drug launches of 2025
Jan 27, 2025 3:00am
2024's top biopharma M&A deals
Jan 13, 2025 3:00am
2024 approvals: Biopharma delivered 55 new drugs, biologics
Jan 2, 2025 3:00am
2024's Fiercest Women in Life Sciences
Nov 18, 2024 3:00am
Fierce 50 of 2024
Sep 9, 2024 5:02am
